ClinicalTrials.gg
CompletedNCT01166282Updated Jul 12, 2021Results posted

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

A Phase 3 interventional study of adalimumab and placebo for adalimumab in Enthesitis Related Arthritis (ERA), sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.

Started
2010
the only one that year
Phase 3
4 of 10
2 open now
Registered
3rd of 10
by date

Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2010, is one of 4 in phase 3, and was the 3rd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).

03

Conditions studied

  • Enthesitis Related Arthritis (ERA)

Keywords

  • inflammatory back pain
  • ankylosing spondylitis
  • sacroiliitis
  • Juvenile Idiopathic Arthritis
  • enthesitis
  • arthritis
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Enthesitis Related Arthritis (ERA) as defined by International League of Associations for Rheumatology (ILAR);
  • Disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;
  • Inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.

Exclusion criteria

Exclusion Criteria:

  • Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA;
  • Psoriasis or a history of psoriasis in the patient or first-degree relative;
  • Presence of Immunoglobulin M (IgM) rheumatoid factor;
  • Presence of systemic JIA;
  • History of inflammatory bowel disease;
  • previous biologic therapy including anti-tumor necrosis factor (anti-TNF) therapy with a potential impact on pediatric ERA;
  • Infection(s) requiring treatment with IV anti-infectives within 30 days prior to Baseline or oral anti-infectives within 14 days prior to Baseline.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Placebo comparator
    Double-blind Placebo EOW

    Placebo for adalimumab every other week (eow) for 12 weeks.

    Biological: placebo for adalimumab

  • Experimental
    Double-blind Adalimumab EOW

    Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.

    Biological: adalimumab

  • Experimental
    Open-label Adalimumab EOW

    Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Adalimumab solution for subcutaneous injection.

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo for adalimumab

    Placebo for adalimumab solution for subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12

    A joint assessment was recorded at all study visits to assess the number of active joints. A total of 72 joints were assessed for swelling not due to deformity or joints with loss of motion (LOM) plus pain and/or tenderness. Total possible scores ranges from 0 (no active joints) to 72 (all active joints). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Last Observation Carried Forward (LOCF) was used for missing data.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Sites of Enthesitis: Change From Baseline to Week 12

    The presence of enthesitis was assessed by pressure at 35 anatomical locations. Enthesitis was classifed as either present or absent. Scores range from 0 to 35, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

    Time frame: Baseline and Week 12

  2. Tender Joint Count (TJC72): Change From Baseline to Week 12

    Seventy-two joints were assessed by pressure on physical examination. Joint tenderness was classified as either present or absent. Scores range from 0 to 72, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

    Time frame: Baseline and Week 12

  3. Swollen Joint Count (SJC68): Change From Baseline to Week 12

    Sixty-eight joints were assessed by physical examination. Joint swelling was classified as present or absent. Scores range from 0 to 68, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

    Time frame: Baseline and Week 12

  4. Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)

    The ACR Pedi30 response is defined as ≥30% improvement in at least 3 of 6 juvenile rheumatoid arthritis (JRA) core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation (NRI) was used for missing data.

    Time frame: Baseline and Week 12

  5. Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)

    The ACR Pedi50 response is defined as ≥50% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. NRI was used.

    Time frame: Baseline and Week 12

  6. Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)

    The ACR Pedi70 response is defined as ≥70% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation NRI was used.

    Time frame: Baseline and Week 12

  7. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either probably related to study drug, possibly related to study drug, probably not related, or not related to study drug. For more details on adverse events please see the AE section below.

    Time frame: Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 212 weeks)

07

Results

Posted Jun 21, 2016

Participant flow

The study included a 30-day screening period.

Double-blind Period
Participant flow — Double-blind Period
MilestoneDouble-blind Placebo EOWDouble-blind Adalimumab EOWOpen-label Adalimumab EOW
Started15310
Completed15310
Not completed000
Open-label Period
Participant flow — Open-label Period
MilestoneDouble-blind Placebo EOWDouble-blind Adalimumab EOWOpen-label Adalimumab EOW
Started0046
Completed0029
Not completed0017
Withdrew: Adverse event006
Withdrew: Withdrawal by subject004
Withdrew: Lack of efficacy002
Withdrew: Remission004
Withdrew: Irregular compliance001

Outcome measures

PrimaryPercent Change in Number of Active Joints With Arthritis From Baseline to Week 12

A joint assessment was recorded at all study visits to assess the number of active joints. A total of 72 joints were assessed for swelling not due to deformity or joints with loss of motion (LOM) plus pain and/or tenderness. Total possible scores ranges from 0 (no active joints) to 72 (all active joints). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Last Observation Carried Forward (LOCF) was used for missing data.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12
percent changeDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12-11.6 ± 100.5-62.6 ± 59.53
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · ANCOVA · p = =0.039 · Mean difference (final values): -51.17 · 95% CI -99.69 to -2.66
SecondaryNumber of Sites of Enthesitis: Change From Baseline to Week 12

The presence of enthesitis was assessed by pressure at 35 anatomical locations. Enthesitis was classifed as either present or absent. Scores range from 0 to 35, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

Time frame:
Baseline and Week 12
Reported as:
Mean · sites of enthesitis
Number of Sites of Enthesitis: Change From Baseline to Week 12
sites of enthesitisDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Baseline7.8 ± 7.498.3 ± 8.89
Week 125.1 ± 8.923.9 ± 6.60
Change from Baseline to Week 12-2.7 ± 4.98-4.4 ± 6.20
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · 1-way ANOVA · p = =0.382 · Mean difference (final values): -1.62 · 95% CI -5.32 to 2.08
SecondaryTender Joint Count (TJC72): Change From Baseline to Week 12

Seventy-two joints were assessed by pressure on physical examination. Joint tenderness was classified as either present or absent. Scores range from 0 to 72, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Tender Joint Count (TJC72): Change From Baseline to Week 12
units on a scaleDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Baseline11.9 ± 9.3413.4 ± 10.49
Week 127.5 ± 8.065.5 ± 8.77
Change from Baseline to Week 12-4.5 ± 8.97-7.9 ± 8.25
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · 1-way ANOVA · p = =0.209 · Mean difference (final values): -3.40 · 95% CI -8.78 to 1.97
SecondarySwollen Joint Count (SJC68): Change From Baseline to Week 12

Sixty-eight joints were assessed by physical examination. Joint swelling was classified as present or absent. Scores range from 0 to 68, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Swollen Joint Count (SJC68): Change From Baseline to Week 12
units on a scaleDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Baseline5.2 ± 3.696.7 ± 7.30
Week 122.8 ± 2.833.2 ± 7.27
Change from Baseline to Week 12-2.4 ± 4.66-3.5 ± 5.61
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · 1-way ANOVA · p = =0.509 · Mean difference (final values): -1.12 · 95% CI -4.49 to 2.26
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)

The ACR Pedi30 response is defined as ≥30% improvement in at least 3 of 6 juvenile rheumatoid arthritis (JRA) core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation (NRI) was used for missing data.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)
percentage of participantsDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)60.071.0
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · Fisher Exact · p = =0.514 · Mean difference (final values): 11 · 95% CI -18.5 to 40.5
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)

The ACR Pedi50 response is defined as ≥50% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. NRI was used.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)
percentage of participantsDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)40.067.7
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · Fisher Exact · p = =0.111 · Mean difference (final values): 27.7 · 95% CI -2.0 to 57.5
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)

The ACR Pedi70 response is defined as ≥70% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation NRI was used.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)
percentage of participantsDouble-blind Placebo EOWDouble-blind Adalimumab EOW
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)20.054.8
Statistical analysis
  • Double-blind Placebo EOW vs Double-blind Adalimumab EOW · Fisher Exact · p = =0.031 · Mean difference (final values): 34.8 · 95% CI 8.1 to 61.6
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either probably related to study drug, possibly related to study drug, probably not related, or not related to study drug. For more details on adverse events please see the AE section below.

Time frame:
Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 212 weeks)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsDouble-blind Placebo EOWDouble-blind Adalimumab EOWAny Adalimumab
Any TEAE82146
TEAEs at least possibly related to study drug4929
Any severe TEAE007
TESAE0110
Any TEAE Leading to Discontinuation of Study007
Death000

Adverse events

Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 212 weeks); SAEs were collected from the time informed consent was obtained (up to 216 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo EOW—0/15 (0%)8/15 (53.3%)
Double-blind Adalimumab EOW—1/31 (3.2%)21/31 (67.7%)
Any Adalimumab—10/46 (21.7%)46/46 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDouble-blind Placebo EOWDouble-blind Adalimumab EOWAny Adalimumab
JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders0/150/312/46
ABDOMINAL PAIN UPPERGastrointestinal disorders0/151/311/46
HEADACHENervous system disorders0/151/311/46
CARDIAC FAILURE CONGESTIVECardiac disorders0/150/311/46
PAINGeneral disorders0/150/311/46
APPENDICITISInfections and infestations0/150/311/46
DISSEMINATED TUBERCULOSISInfections and infestations0/150/311/46
PNEUMONIAInfections and infestations0/150/311/46
URINARY TRACT INFECTIONInfections and infestations0/150/311/46
BURNS SECOND DEGREEInjury, poisoning and procedural complications0/150/311/46
Most frequent other events
Showing 10 of 178
Most frequent other events
EventDouble-blind Placebo EOWDouble-blind Adalimumab EOWAny Adalimumab
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/153/3116/46
NASOPHARYNGITISInfections and infestations1/150/3111/46
HEADACHENervous system disorders0/153/3110/46
DIARRHOEAGastrointestinal disorders0/151/318/46
GASTROENTERITISInfections and infestations0/152/318/46
PHARYNGITISInfections and infestations0/151/317/46
PHARYNGOTONSILLITISInfections and infestations0/150/317/46
ABDOMINAL PAINGastrointestinal disorders0/151/316/46
PYREXIAGeneral disorders0/150/316/46
JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders1/150/316/46

Baseline characteristics

Intent-to-treat (ITT) population: All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Double-blind Placebo EOWDouble-blind Adalimumab EOWTotal
Mean11.9 ± 2.8513.4 ± 2.8612.9 ± 2.92
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Placebo EOWDouble-blind Adalimumab EOWTotal
Female6915
Male92231
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, Unnebrink K, Anderson JK. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken). 2015 Nov;67(11):1503-12. doi: 10.1002/acr.22657. PubMed 26223543 ↗
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Nov 2012 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2010
First posted
Jul 21, 2010
Start
Sep 2010
Primary completionActual
Nov 2012
CompletionActual
Dec 2015
Results first posted
Jun 21, 2016
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01166282
Responsible party
Sponsor
First posted
Jul 21, 2010
Start date
Sep 2010
Primary completion
Nov 2012
Completion
Dec 2015
Results posted
Jun 21, 2016
Last update
Jul 12, 2021

Study contacts

Jaclyn Anderson, DO, MS
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion